Arbutus Biopharma Corp
Closed
4.31 2.62
Overview
Share price change
24h
Min
4.3
Max
4.32
Income | 4M -3.8M |
|---|---|
Sales | 522K 1.1M |
EPS | -0.014 |
Profit margin | -357.374 |
Employees | 19 |
EBITDA | 75K -7.6M |
Next Earnings | 13 May 2026 |
|---|
Market Cap | 4.4M 843M |
|---|---|
Previous open | 1.69 |
Previous close | 4.31 |
Technical Score
By Trading Central
Confidence
Weak Bearish Evidence
Arbutus Biopharma Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Arbutus Biopharma Corp Forecast
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
